GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hard to Treat Diseases Inc (OTCPK:HTDS) » Definitions » Net Margin %

HTDS (Hard to Treat Diseases) Net Margin % : 0.00% (As of . 20)


View and export this data going back to . Start your Free Trial

What is Hard to Treat Diseases Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Hard to Treat Diseases's Net Income for the three months ended in . 20 was $0.00 Mil. Hard to Treat Diseases's Revenue for the three months ended in . 20 was $0.00 Mil. Therefore, Hard to Treat Diseases's net margin for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Hard to Treat Diseases's Net Margin % or its related term are showing as below:


HTDS's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -143.61
* Ranked among companies with meaningful Net Margin % only.

Hard to Treat Diseases Net Margin % Historical Data

The historical data trend for Hard to Treat Diseases's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hard to Treat Diseases Net Margin % Chart

Hard to Treat Diseases Annual Data
Trend
Net Margin %

Hard to Treat Diseases Quarterly Data
Net Margin %

Competitive Comparison of Hard to Treat Diseases's Net Margin %

For the Biotechnology subindustry, Hard to Treat Diseases's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hard to Treat Diseases's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hard to Treat Diseases's Net Margin % distribution charts can be found below:

* The bar in red indicates where Hard to Treat Diseases's Net Margin % falls into.



Hard to Treat Diseases Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Hard to Treat Diseases's Net Margin for the fiscal year that ended in . 20 is calculated as

Net Margin=Net Income (A: . 20 )/Revenue (A: . 20 )
=/
= %

Hard to Treat Diseases's Net Margin for the quarter that ended in . 20 is calculated as

Net Margin=Net Income (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hard to Treat Diseases  (OTCPK:HTDS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Hard to Treat Diseases Net Margin % Related Terms

Thank you for viewing the detailed overview of Hard to Treat Diseases's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hard to Treat Diseases Business Description

Traded in Other Exchanges
N/A
Address
2655 Ulmerton Road, No. 338, Clearwater, FL, USA, 33762
Hard to Treat Diseases Inc operates medical and cosmetics company in Europe, and Mainland China. It is s also in the process of developing its own stem cell bank.

Hard to Treat Diseases Headlines

No Headlines